Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system.
about
Opposite role of Bax and BCL-2 in the anti-tumoral responses of the immune systemTherapeutic cancer vaccines: past, present, and futureAn update on vaccine therapy and other immunotherapeutic approaches for glioblastomaCombining cytotoxic and immune-mediated gene therapy to treat brain tumorsDownregulation of major histocompatibility complex antigens in invading glioma cells: stealth invasion of the brain.EGFRvIII-targeted immunotoxin induces antitumor immunity that is inhibited in the absence of CD4+ and CD8+ T cellsAn overview of cancer immunotherapy.Progress in active-specific immunotherapy of brain malignancies.Normal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like properties.RNA as a tumor vaccine: a review of the literature.Modulating T-cell immunity to tumours: new strategies for monitoring T-cell responses.All in the head: obstacles for immune rejection of brain tumours.GM-CSF-based cancer vaccines.Cell-mediated immunotherapy: a new approach to the treatment of malignant glioma.Unarmed, tumor-specific monoclonal antibody effectively treats brain tumorsInoculation site from a cutaneous melanoma patient treated with an allogeneic therapeutic vaccine: a case report.Inhibitors of Glioma Growth that Reveal the Tumour to the Immune System.Gene therapy for malignant glioma.Transplantation immunology and the central nervous system.The tumor microenvironment expression of p-STAT3 influences the efficacy of cyclophosphamide with WP1066 in murine melanoma models.Sequential immunotherapy by vaccination with GM-CSF-expressing glioma cells and CTLA-4 blockade effectively treats established murine intracranial tumorsImmunotherapy of malignant brain tumors.Immunotherapy for malignant glioma: current approaches and future directions.Immunotherapy for human glioma: innovative approaches and recent results.Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors.Identification of SOX2 as a novel glioma-associated antigen and potential target for T cell-based immunotherapy.Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trialStereotactic radiosurgery: adjacent tissue injury and response after high-dose single fraction radiation. Part II: Strategies for therapeutic enhancement, brain injury mitigation, and brain injury repair.Anti-tumor activity and trafficking of self, tumor-specific T cells against tumors located in the brainIL-3 is required for increases in blood basophils in nematode infection in mice and can enhance IgE-dependent IL-4 production by basophils in vitroExpression of FMS-like tyrosine kinase 3 ligand by oncolytic herpes simplex virus type I prolongs survival in mice bearing established syngeneic intracranial malignant glioma.Vaccines for glioblastoma and high-grade glioma.Clinical trials in cellular immunotherapy for brain/CNS tumors.Myeloid-derived suppressor cells in glioma.Rindopepimut: a promising immunotherapeutic for the treatment of glioblastoma multiforme.Novel chemotherapeutics and other therapies for treating high-grade glioma.Complementary contribution of CD4 and CD8 T lymphocytes to T-cell infiltration of the intact and the degenerative spinal cordImmune infiltration of tumor microenvironment following immunotherapy for glioblastoma multiforme.Kinase inhibitor Sorafenib modulates immunosuppressive cell populations in a murine liver cancer model.Adenovirus-mediated interleukin-12 gene therapy for prostate cancer: suppression of orthotopic tumor growth and pre-established lung metastases in an orthotopic model.
P2860
Q24804354-6185A9B1-CF0F-4708-AF02-FA2D98AAFAE8Q26863283-E3D096B1-70A5-4022-8E32-13FE50CF646CQ27024830-248BB812-BAC7-4CF0-BE7A-20355EEA81A4Q31013320-D3A8A3C1-38D4-440A-9EFF-931CCB918018Q31148056-B11F08F6-4D63-4A22-87ED-D5671A872A08Q33758468-42256853-D3E0-4871-8FBF-AC54730EC9B1Q33940388-3A840B9A-6AE2-4803-A535-1D7AF85F5F7CQ34075068-A1A9C97A-D93C-4602-AACB-DA9918D7E1EBQ34132823-71095EE8-A8DD-4480-8677-DD5D80FA63DAQ34266409-6200A2B7-FC77-48E2-AA40-F54025DD50B5Q34791108-2D65492D-3E8E-4EB5-827B-0E254D500C3FQ34842204-EA77C3C1-2C3A-49B6-8684-ED336C0AC07BQ35005952-4614C9FA-0231-4A88-ACEB-6297EE85A438Q35113661-65C79A8C-9F49-44DA-B4D6-F37F65E49481Q35162055-5055D324-3540-4789-A80F-0D2734194DE2Q35229087-C8FB10E5-04C7-45D9-917D-5A9439478C6EQ35440540-2A96B1A3-A038-4DEF-BE62-B7EA49E74B67Q35673628-EB8F002F-1969-49AD-B7F7-ED5893692048Q35772684-05F61987-DC97-497B-84EB-E44759AB5AE7Q35871559-D12A3759-6AF9-4836-B51A-1B09D074C806Q35962460-B1FCE498-CAE8-4555-BA32-DF7A5CB5A22EQ36162929-932E83DC-1C50-4ABA-87A4-9C98F16CB89EQ36273693-BA29F9D8-1AC4-4FD4-A729-2387E635341AQ36284489-9E422266-B637-459A-BC41-46015742349DQ36380683-F78A2DBE-1E91-43EB-89B5-0B591D7FC60AQ36610286-C0F0E790-0660-4CC0-9E0C-BFD03F31BB7FQ36671200-1A5DF799-E757-48AA-A622-FB982E98029AQ36802285-F7E9307D-4B26-45C2-A6A9-D6E046B5AD73Q37037932-A6852C16-9A6F-4EBF-9511-B9D0682EBDE8Q37458388-8A057813-BB46-4E3D-8271-C28C81716E3DQ37579001-93373E65-4645-41E0-AC8B-FEEFF7D6ABC4Q37892597-2DA8F48A-2B90-44CA-81E6-93E2631EAB24Q38094811-D5A24DEB-DAB0-466B-8509-67E41D2565E7Q38161536-8828DA4B-4022-4FD6-B2C6-55056A7620F8Q38245925-FFE69624-A641-40AA-920E-A7A9C7C0C383Q38569802-76E64EFF-8EE8-4938-AE95-32511231997DQ38621546-36B59A80-A4AF-4A4D-8F32-B896ABB5EA9CQ38864816-787E1786-F260-43BE-B9E2-A1D793FBEAFFQ39592084-BADFDB35-ACBA-4A8C-970F-5436091FFFD9Q40937528-495FB96C-1C02-4810-9594-D25FE353727C
P2860
Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 1996
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Subcutaneous vaccination with ...... leged" central nervous system.
@en
Subcutaneous vaccination with ...... leged" central nervous system.
@nl
type
label
Subcutaneous vaccination with ...... leged" central nervous system.
@en
Subcutaneous vaccination with ...... leged" central nervous system.
@nl
prefLabel
Subcutaneous vaccination with ...... leged" central nervous system.
@en
Subcutaneous vaccination with ...... leged" central nervous system.
@nl
P2093
P2860
P356
P1476
Subcutaneous vaccination with ...... leged" central nervous system.
@en
P2093
P2860
P304
10399-10404
P356
10.1073/PNAS.93.19.10399
P407
P577
1996-09-01T00:00:00Z